⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170737 | 1.00 | — | — | |
| SCHEMBL178378 | 1.00 | — | — | |
| Fluoride SCHEMBL28553579 | 0.97 | KMT2A (0.39) | — | |
| Ammonia Solution, Strong SCHEMBL27597475 | 0.97 | — | — | |
| SCHEMBL28381148 | 0.93 | KMT2A (0.37) | — | |
| Methoxymethane SCHEMBL28360320 | 0.93 | LMNA (0.40) | — | |
| SCHEMBL13486887 | 0.92 | — | — | |
| SCHEMBL13486886 | 0.92 | — | — | |
| SCHEMBL153432 | 0.92 | — | — | |
| SCHEMBL28553578 | 0.91 | KMT2A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137674-A2 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024054618-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023239665-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS INCLUDING SARS-COV-2 | GILEAD SCIENCES, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023230609-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023170014-A1 | ECO-FRIENDLY ADHESIVE FORMULATION CONTAINING 2-METHYL TETRAHYDROFURAN | ARLANXEO DEUTSCHLAND GMBH (DE) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023164358-A1 | GLP-1R MODULATING COMPOUNDS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023154426-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4223750-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND WHICH CONTAINS PYRIMIDINE | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223751-A1 | BENZAMIDE COMPOUND AND USE THEREOF | Humanwell Healthcare (Group) Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20080293722-A1 | Ion Channel Modulators | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293722-A1 | Ion Channel Modulators | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20080058337-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-03-06 | — | — | US | disclosed |
| US-7304071-B2 | Protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070129346-A1 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2007-06-07 | — | — | US | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007022258-A1 | NOVEL HIGH AFFINITY THIOPHENE-BASED AND FURAN-BASED KINASE LIGANDS | SCHERING CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2005090291-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |